Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Inclusion Criteria: * Participant must be at least 18 years of age at the time of signing the informed consent. * Known or highly suspected CNS pathology (contrast-enhancing CNS lesion) referred for contrast-enhanced MRI of the CNS. * Male and female. * Estimated glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m\^2. Exclusion Criteria: * Considered clinically unstable or has a concomitant/intercurrent condition (e.g. COVID-19 infection) that would not allow participation for the full planned study period (i.e. period 1, 2 or both) in the judgement of the investigator. * Severe cardiovascular disease. * Patients undergoing liver transplantation. * Any contraindication to MRI examinations. * History of severe allergic or anaphylactic/anaphylactoid reaction to any allergen including drugs and contrast agents, foods, chemicals or other substances. * History of allergic asthma and/ or atopic dermatitis. * Suspected lesions or suffering from any of the following CNS diseases/lesion types as the main indication for MRI: * Lepto-meningeal disease (e.g. leptomeningeal carcinomatosis). Dural lesions (e.g. meningiomas) fulfilling inclusion criteria #2 are not excluded * Pituitary adenomas (macro and micro) * Tumors of the choroid plexus * Tumors of the pineal gland * Dermoid/epidermoid tumors * Infectious disease (e.g. brain abscess, cisticercosis, etc.) * Venous angiomas * Subacute/chronic ischemia * Encephalitis * Multiple sclerosis (acute and chronic) …